Doyle Mittie 4

What Happened

• Doyle Mittie, Chief Medical Officer of Avalo Therapeutics (AVTX), exercised stock option derivatives and sold the resulting shares on June 30, 2026. He exercised 2,875 shares at $12.65 (cost $36,369) and 1,779 shares at $8.04 (cost $14,303), acquiring 4,654 shares total for about $50,672 in exercise costs. Those 4,654 shares were then sold in an open-market transaction at $20.00 per share for proceeds of $93,080. The filing also shows the derivative positions cancelled (listed as dispositions at $0.00), reflecting the option exercises.

Key Details

• Transaction date: 2026-06-30; Sale price: $20.00; Exercise prices: $12.65 and $8.04
• Shares acquired by exercise: 4,654 (2,875 + 1,779); Shares sold: 4,654
• Exercise cost (approx.): $50,672; Sale proceeds: $93,080
• Reported under a Rule 10b5-1 trading plan adopted Nov 13, 2025 (Footnote F1)
• Vesting notes: one option series vested 25% on Jul 15, 2025 with monthly vesting thereafter (F2); another vested 25% on Jan 28, 2026 with monthly vesting thereafter (F3)
• Shares owned after the transaction: not specified in the provided filing excerpt
• Filing date: Form 4 filed Jul 2, 2026 (covering 6/30/2026 transactions) — not indicated as late in the filing

Context

• This was an option exercise followed by an immediate sale of all shares obtained (a common cashless-like outcome). The presence of a 10b5-1 trading plan indicates the sale was executed under a pre-established plan, which is intended to avoid trading based on nonpublic information. The derivative disposals at $0.00 reflect cancellation/settlement of the exercised options, not gifts or separate cash sales.